This article shares the insights of a study presented at Digestive Disease Week in 2019. This retrospective chart review is “the largest case study to date to examine oral vancomycin in patients with UC-PSC.”

This research showed that “oral vancomycin safely induced and maintained remission of ulcerative colitis among a subset of patients with ulcerative colitis and associated primary sclerosing cholangitis, including those who had undergone liver transplantation.”

Below are some of the most exciting and hopeful quotes from the article:

• – In 9 to 36 months of follow-up, clinical and endoscopic response/remission was maintained by all patients. No side effects with oral vancomycin were noted.
• – “The patients in our study achieved sustained clinical remission within a few days or weeks of starting oral vancomycin and, even more importantly, achieved mucosal healing on endoscopy,” says Dr. Aline Charabaty.
• – Charabaty recommended that, if a patient does not respond to mesalamine, oral vancomycin should be initiated before moving to a biologic.

Check out this incredible article for more details!